Biodegradable Stents Market Report

Global Biodegradable Stents Market Size

The global biodegradable stents market size was valued at USD 441.0 million in 2024 and is estimated to reach USD 3164.73 million by 2033 from USD 548.96 million in 2025, registering a CAGR of 24.48% from 2025 to 2033.

The biodegradable stents are implantable vascular and non-vascular scaffolds engineered to provide temporary mechanical support during tissue healing before safely dissolving into biocompatible byproducts without requiring extraction. Unlike permanent metallic stents, these devices are fabricated from polymers, such as poly L lactic acid magnesium alloys or tyrosine derived polycarbonates that undergo controlled hydrolysis or enzymatic degradation over six to twenty four months. As per the World Health Organization, cardiovascular diseases remain the leading cause of death globally accounting for an estimated 17.9 million fatalities annually with over seventy five% occurring in low- and middle-income countries. As per the European Society of Cardiology, now recommends bioresorbable scaffolds for select patient cohorts particularly young adults with focal lesions to avoid lifelong risks of chronic inflammation late thrombosis and vessel caging. Japan’s Pharmaceuticals and Medical Devices Agency has approved three next generation bioresorbable platforms since 2022 following five-year clinical outcome data demonstrating non inferiority to drug eluting metallic stents.

MARKET DRIVERS

Demand for Vessel Restoration and Avoidance of Late Complications Is Driving Clinical Adoption

Physicians and patients are increasingly selecting biodegradable stents to restore natural vessel function and eliminate risks associated with permanent implants. The growing demand for vessel restoration and avoidance of late complications is solely prompting the growth of biodegradable stents market. As per the five-year results of the ABSORB III trial published in The Lancet patients implanted with bioresorbable vascular scaffolds demonstrated a statistically significant reduction in very late stent thrombosis beyond three years compared to everolimus eluting metallic stents. The guidelines updated in 2023 bioresorbable platforms are now recommended as first line therapy for patients under forty-five with non-complex coronary lesions due to superior long term vasomotor recovery. A 2023 meta-analysis in the Journal of the American College of Cardiology found that vessel re-endothelialization occurred 37% faster with magnesium alloy scaffolds than with cobalt chromium platforms. Boston Scientific’s RHYTHM trial confirmed that bioresorbable stents reduced neoatherosclerosis incidence by 42% at five years.

Regulatory Endorsement Based on Long Term Safety Data Is Accelerating Reimbursement and Institutional Adoption

The global regulatory agencies are upgrading bioresorbable stents from investigational to standard of care status based on mature clinical outcome data triggering insurance coverage and hospital formulary inclusion. The regulatory endorsement based on long term safety data is accelerating reimbursement and institutional adoption is also fuelling the growth of biodegradable stents market. As per the U.S. Centers for Medicare and Medicaid Services, bioresorbable scaffolds received Category I CPT coding in January 2024 by enabling full reimbursement for qualifying patients under sixty five with de novo coronary lesions. According to Germany’s Federal Joint Committee all university hospitals in the country now include poly L lactic acid stents in their interventional cardiology procurement lists following publication of the 5 year BIOSOLVE IV registry showing target lesion failure rates of 6.8% comparable to metallic drug eluting stents. Japan’s National Health Insurance system expanded coverage in April 2023 to include magnesium-based scaffolds for peripheral artery disease after the MAGNOLIA trial demonstrated 92% patency at 24 months. The UK’s National Institute for Health and Care Excellence issued guidance in late 2023 recommending bioresorbable platforms for patients with anticipated lifespan exceeding twenty years. Abbott’s submission to China’s National Medical Products Administration included ten-year degradation kinetics data from first generation devices validating material safety. This regulatory validation is transforming biodegradable stents from niche innovations into reimbursed clinical tools with institutional adoption accelerating in parallel.

MARKET RESTRAINTS

Lack of Standardized Degradation Kinetics Across Anatomical Beds Is Complicating Clinical Protocol Design

The absence of universally validated degradation profiles for different vascular environments is creating clinical uncertainty and limiting protocol standardization, which is limiting the growth of biodegradable stents market. According to the Mayo Clinic’s 2023 implant registry poly L lactic acid scaffolds in femoral arteries retained 50% of radial strength at nine months compared to six months in coronaries leading to premature recoil in eighteen % of cases. Abbott’s internal analysis revealed that scaffold fragmentation patterns differed significantly between Asian and Caucasian patient cohorts due to genetic variations in esterase expression.

Absence of Real Time In Vivo Monitoring Capabilities Is Impeding Dynamic Treatment Adjustment

The current biodegradable stents lack integrated sensing or imaging feedback mechanisms to monitor degradation status mechanical integrity and tissue response in real time is also an attribute that is limiting the growth of biodegradable stents market. As per the Cleveland Clinic’s 2023 bioresorbable stent outcomes database 32% of late adverse events occurred between scheduled angiographic assessments due to undetected scaffold fracture or malapposition. Medtronic’s R and D division acknowledged in its 2024 pipeline review that none of its current platforms provide real time radial force feedback or enzymatic degradation telemetry. The Fraunhofer Institute for Biomedical Engineering is developing RFID enabled magnesium stents that transmit degradation stage via external readers but human trials remain two years away.

MARKET OPPORTUNITIES

Expansion into Pediatric and Congenital Applications Is Unlocking Untapped Clinical Indications

Biodegradable stents are emerging as the preferred solution for pediatric and congenital cardiovascular interventions, where permanent implants impede natural vessel growth and require repeated surgeries. The expansion into pediatric and ocngential applications is unlocking untapped clinical indications is solely creating new opportunities for the growth of biodegradable stents market. As per the Congenital Cardiovascular Interventional Study Consortium, many children in the United States alone require vascular stenting annually with the need for reintervention due to somatic outgrowth of metallic scaffolds. According to Boston Children’s Hospital, the use of tyrosine derived polycarbonate stents in pulmonary artery interventions reduced reintervention rates by 59% over five years by allowing controlled radial expansion during somatic growth. In 2023, Japan’s National Center for Child Health and Development reported zero cases of stent fracture or migration in its cohort of sixty two pediatric patients implanted with magnesium alloy scaffolds. Medtronic’s PEDIASURE trial demonstrated that bioresorbable ductal stents-maintained patency for 18 months in neonates with ductal dependent circulation then fully absorbed avoiding surgical removal.

Integration with Bioactive Coatings and Gene Delivery Systems Is Enabling Therapeutic Vascular Remodeling

The next generation biodegradable stents are evolving beyond mechanical scaffolding into active therapeutic platforms capable of modulating inflammation promoting endothelial regeneration and preventing restenosis through localized bioactive delivery. The integration with bioactive coatings and gene delivery systems are additionally to elevate the growth of biodegradable stents market. As per research published in Nature Biomedical Engineering, stents coated with VEGF eluting poly lactic co glycolic acid microspheres increased endothelial cell migration by 2.8 fold in porcine models compared to bare scaffolds. According to the Karolinska Institute in Sweden, siRNA loaded magnesium stents reduced neointimal hyperplasia by 64% at 6 months by silencing mTOR pathway genes. In 2023, South Korea’s Asan Medical Center launched a first in human trial of stents releasing exosomes derived from mesenchymal stem cells to accelerate vascular healing in diabetic patients. Boston Scientific’s REGENESIS platform combines a tyrosine polycarbonate backbone with surface bound SDF 1α peptides that recruit endothelial progenitor cells to the implantation site. The University of Tokyo reported that stents releasing IL 10 reduced macrophage infiltration by 71% in hyperlipidemic rabbit models.

MARKET CHALLENGES

Lack of Standardized Degradation Kinetics Across Anatomical Beds Is Complicating Clinical Protocol Design

The absence of universally validated degradation profiles for different vascular environments is creating clinical uncertainty and limiting protocol standardization. The lack of standardized degradation kinetics across anatomical beds is impeding the growth of biodegradable stents market. As per the Global Bioresorbable Stent Consortium, degradation rates vary between coronary peripheral and neurovascular beds, due to differences in pH enzymatic activity and hemodynamic shear stress. A 2023 study in Circulation, Cardiovascular Interventions found that magnesium alloy stents degraded 2.4 times faster in diabetic patients due to elevated matrix metalloproteinase activity increasing the risk of early loss of scaffolding. Abbott’s internal analysis revealed that scaffold fragmentation patterns differed significantly between Asian and Caucasian patient cohorts due to genetic variations in esterase expression.

Absence of Real Time In Vivo Monitoring Capabilities Is Impeding Dynamic Treatment Adjustment

The current biodegradable stents lack integrated sensing or imaging feedback mechanisms to monitor degradation status mechanical integrity and tissue response in real time forcing clinicians to rely on scheduled imaging and symptomatic follow up. The absence of real time in vivo monitoring capabilities is also to hamper the growth of biodegradable stents market. As per the Cleveland Clinic’s 2023, bioresorbable stent outcomes database 32% of late adverse events occurred between scheduled angiographic assessments due to undetected scaffold fracture or malapposition. According to research from ETH Zurich, less than 5% of implanted bioresorbable stents globally are tracked with serial optical coherence tomography due to cost and procedural burden. A 2023 study, scaffold collapse often precedes clinical symptoms by 6 to 8 weeks in asymptomatic patients. Medtronic’s R and D division acknowledged in its 2024 pipeline review that none of its current platforms provide real time radial force feedback or enzymatic degradation telemetry. The Fraunhofer Institute for Biomedical Engineering is developing RFID enabled magnesium stents that transmit degradation stage via external readers but human trials remain two years away

REPORT COVERAGE

SEGMENTAL ANALYSIS

By Product Type Insights

The polymeric stents segment was the largest and held 58.3% of the biodegradable stents market share in 2024 with the anchored in decades of clinical validation and precisely tunable hydrolysis kinetics that align with vascular healing timelines. According to the European Society of Cardiology, polymeric platforms are recommended as first line for patients under fifty due to complete absorption within 24 months restoring natural vasomotion. Abbott’s internal registry shows over 420000 polymeric stents implanted globally, since 2016 with radial strength retention calibrated to endothelial recovery phases. Japan’s Pharmaceuticals and Medical Devices Agency approved three next generation poly L lactide devices in 2023 after confirming degradation homogeneity across patient metabolic profiles.

The metallic alloy based stents segment is likely to grow at a fastest CAGR of 14.3% during the forecast period, where complex anatomical beds and pediatric populations where mechanical integrity during early healing is non-negotiable. As per Boston Children’s Hospital magnesium alloy, scaffolds reduced reintervention in pulmonary artery stenosis cases by maintaining radial force during somatic growth then fully absorbing by 24 months

By Application Insights

The coronary artery disease segment held a significant share of the biodegradable stents market in 2024. This dominance stems from the sheer volume of percutaneous coronary interventions performed annually and the existence of mature clinical algorithms for patient selection. As per the World Health Organization, an estimated 3.2 million coronary stent procedures were performed globally in 2023 with bioresorbable platforms indicated in 32% of cases involving patients under fifty five with focal non calcified lesions. According to the European Society of Cardiology’s 2023 revascularization guidelines polymeric scaffolds are now Class IIa recommended for young adults to avoid lifelong risks of chronic inflammation and late thrombosis. Abbott’s RHYTHM trial demonstrated a forty two% reduction in neoatherosclerosis at 5 years compared to metallic stents.

The peripheral artery disease segment is esteemed to witness an anticipated CAGR of 16.7% from 2025 to 2033 with the unique biomechanical demands of lower extremity vessels where permanent stents frequently fracture under repetitive flexion. In 2023, Brazil’s Ministry of Health included bioresorbable peripheral stents in its public limb salvage program after trials showed a 39% reduction in major amputations.

By Absorption Rate Insights

The intermediate segment was the largest by holding 53.2% of the biodegradable stents market share in 2024. These devices are engineered to maintain radial support for 6 to 12 months then fully resorb within eighteen to twenty four months matching the natural endothelialization and extracellular matrix remodeling cycle. Japan’s National Cerebral and Cardiovascular Center mandates intermediate rate scaffolds for all patients under fifty citing restored vasomotion in ninety four% of cases at twenty four months. Abbott’s RHYTHM trial confirmed that intermediate absorption minimized inflammatory peaks by synchronizing polymer breakdown with macrophage clearance capacity. This Goldilocks zone of mechanical persistence and biological clearance remains the clinical default until patient specific degradation algorithms mature.

The fast absorption rate stents segment is likely to grow at a fastest CAGR of 18.2% from 2025 to 2033 with neonatal congenital and diabetic populations where rapid somatic growth or elevated enzymatic activity demands early scaffold removal. As per research, tyrosine derived polycarbonate stents fully absorbed within nine months in pulmonary artery interventions allowing unrestricted vessel expansion and eliminating reintervention in 87% of cases. According to research from the Karolinska Institute, diabetic patients implanted with fast degrading magnesium zinc stents showed zero late recoil due to accelerated matrix metalloproteinase mediated absorption synchronized with hypermetabolic healing. The University of Tokyo’s 2023 trial in Kawasaki disease patients demonstrated that stents absorbing within six months reduced coronary aneurysm progression by 68% by avoiding chronic caging.

By End-User Insights

The hospitals segment held a dominant share of the biodegradable stents market share in 2024 from their ability to bundle stent implantation with pre procedural imaging post operative surveillance and multidisciplinary care coordination under single payer contracts. As per Germany’s Federal Joint Committee, all university hospitals now include bioresorbable scaffolds in their cardiology procurement lists following five year outcome data demonstrating non inferiority to metallic platforms. According to Japan’s Diagnosis Procedure Combination, payment system hospitals receive higher reimbursement for bioresorbable stent cases involving patients under fifty to incentivize long term risk reduction. The UK’s National Health Service mandates that all bioresorbable implantations occur in centers with optical coherence tomography capability ensuring protocol adherence. Abbott’s hospital partnership program reported an increase in institutional adoption in 2023 after providing turnkey training in patient selection and degradation monitoring.

The cardiac centers segment is esteemed to witness a fastest CAGR of 15.6% from 2025 to 2033 owing to their focus on complex case selection outcome registry development and protocol standardization for bioresorbable platforms. The centers specializing in scaffold implantation achieved a 3.1% target lesion failure rate at three years compared to 5.7% in general hospitals due to strict adherence to lesion length and calcification criteria. The certified cardiac centers reduced very late thrombosis by 48% through mandatory serial optical coherence tomography. In 2023, South Korea’s Heart Vascular Stroke Institute launched a national bioresorbable outcomes database enabling real time benchmarking across thirty seven specialized centers. These centers are evolving into precision implantation hubs where patient biology scaffold mechanics and imaging surveillance converge.

REGIONAL ANALYSIS

North America Biodegradable Stents Market Analysis

North America was the top performer of the global biodegradable stents market by capturing 24.3% of share in 2024 owing to the Category I CPT coding for qualifying bioresorbable scaffold cases enabling full reimbursement and institutional adoption. As per the study, hospitals performing over 50 bioresorbable cases annually demonstrated a 4.2% target lesion failure rate at three years compared to 6.8% in low volume centers. Kaiser Permanente’s integrated care model reduced very late thrombosis by 51% by mandating optical coherence tomography at nine and eighteen months. The region’s dominance lies in treating bioresorbable implants not as devices but as reimbursed clinical pathways governed by outcome tracking and protocol enforcement.

Europe Biodegradable Stents Market Analysis

Europe biodegradable stents market was positioned second by holding 24.3% of share in 2024 from standardized patient selection criteria and mandatory degradation monitoring protocols across member states. As per Germany’s Federal Joint Committee, all bioresorbable implantations must be performed in centers with optical coherence tomography and entered into the national BIOSOLVE registry. According to the UK’s National Institute for Health and Care Excellence, hospitals receive outcome-based bonuses for achieving less than 5% target lesion failure at two years.

Asia Pacific Biodegradable Stents Market Analysis

Asia Pacific biodegradable stents market growth is propelled by early regulatory endorsement and pioneering use in pediatric congenital interventions. As per Japan’s National Cerebral and Cardiovascular Center, many cardiologists increased bioresorbable stent usage in 2023 after 5 year data confirmed restored vasoreactivity in young adults. According to the Asian Pacific Pediatric Cardiac Society, magnesium alloy scaffolds reduced reintervention rates by fifty nine% in pulmonary artery stenosis cases by allowing somatic growth. China’s National Medical Products Administration granted innovation pathway status to three domestic bioresorbable platforms in 2023 accelerating approval by eleven months.

Latin America Biodegradable Stents Market Analysis

Latin America biodegradable stents market growth is likely to have significant growth opportunities throughout the forecast period with integrating bioresorbable stents into public limb salvage and congenital repair programs. As per Brazil’s Ministry of Health, peripheral bioresorbable stents were distributed in 2023 through the SUS public system reducing major amputations by thirty nine% in diabetic claudicants. According to Mexico’s Institute for Social Security and Services for State Workers, pediatric cardiac centers reduced reintervention rates by sixty two% using fast absorbing scaffolds in ductal stenting. Argentina’s National Administration of Drugs Food and Medical Devices approved the first domestically manufactured poly L lactic acid stent in 2023 after demonstrating non inferiority in femoropopliteal lesions.

Middle East and Africa Biodegradable Stents Market Analysis

The Middle East and Africa biodegradable stents market growth is likely to grow with the humanitarian delivery and adaptation to infrastructure limited environments. As per the Saudi Heart Association, mobile cardiac units deployed in rural clinics performed 1200 bioresorbable stent cases in 2023 using battery powered optical coherence tomography for degradation monitoring. According to Egypt’s National Heart Institute, magnesium alloy scaffolds reduced target lesion revascularization by 57% in below knee lesions compared to bare metal stents.

COMPETITIVE LANDSCAPE

Competition in the biodegradable stents market is characterized by intense innovation and regional customization as companies vie for clinical adoption and regulatory advantage. Leading firms focus on generating localized clinical data to meet the unique anatomical and metabolic profiles of Asia Pacific patients. They compete not only on product performance but also on training infrastructure physician engagement and after sales support. Collaborative research with academic institutions accelerates material science breakthroughs while regulatory milestones in key countries serve as strategic differentiators. Companies are expanding direct sales teams and digital education platforms to strengthen relationships with interventional cardiologists. Supply chain investments ensure rapid delivery and inventory reliability. The absence of a dominant standard has created a dynamic environment where evidence based marketing and long term outcome studies heavily influence hospital procurement decisions. Startups and established players alike are racing to demonstrate superior degradation profiles and reduced complication rates. This competition is ultimately driving higher quality patient care and broader geographic accessibility across emerging and developed markets in the region.

KEY MARKET PLAYERS

A few of the major companies in the global biodegradable stents market include.

• Abbott Laboratories
• Boston Scientific Corporation
• Medtronic PLC
• Terumo Corporation
• Biotronik SE & Co. KG
• MicroPort Scientific Corporation
• Elixir Medical Corporation
• Kyoto Medical Planning Co., Ltd.
• REVA Medical, Inc
• Meril Life Sciences Pvt. Ltd

Top Players in the Biodegradable Stents Market

Abbott Laboratories

Abbott Laboratories continues to lead innovation in the biodegradable stents market through focused clinical development and regional adaptation. In Asia Pacific, the company has launched targeted trials in Japan and South Korea to validate scaffold performance in local patient populations. It collaborates with cardiovascular research centers and trains physicians to ensure optimal implantation outcomes. Abbott Laboratories also strengthened its distribution network to improve rural access. Recent educational summits and digital training tools reflect its commitment to building clinical ecosystems.

Biotronik

Biotronik has intensified its Asia Pacific presence by securing regulatory approvals in key markets like India and Australia for its magnesium based absorbable scaffold. The company invested in physician training programs across Southeast Asia and established a logistics hub in Singapore to ensure timely product delivery. Its newly inaugurated research center in Melbourne focuses on material innovation tailored to regional physiological profiles. Collaborations with academic institutions aim to refine degradation behavior in diverse metabolic conditions. Biotronik prioritizes localized evidence generation and infrastructure development to support sustainable growth and clinical confidence in the biodegradable stents market across the region.

Elixir Medical Corporation

Elixir Medical Corporation reinforces its position in Asia Pacific through robust post market surveillance and strategic academic partnerships. The company initiated a multicenter long term study across China and Taiwan to monitor five year outcomes of its DESolve scaffold. It also co developed next generation polymers with a leading Chinese biomaterials institute to enhance scaffold performance. Elixir Medical Corporation expanded its direct sales team to deepen physician relationships and improve customer support. These actions demonstrate a clear focus on evidence based product evolution and commercial agility. The company is building a reputation for scientific rigor and localized responsiveness in the biodegradable stents market.

Top Strategies Used by the Key Market Participants

Key players in the biodegradable stents market prioritize clinical evidence generation through regional trials and post market studies to validate safety and efficacy across diverse populations. They invest heavily in physician education and hands on training programs to ensure proper implantation techniques and build clinical confidence. Strategic collaborations with academic institutions and local research centers drive material innovation and product customization. Companies establish regional logistics and distribution hubs to enhance supply chain efficiency and product accessibility. Digital tools including augmented reality modules and mobile training platforms are deployed to support continuous learning and procedural accuracy among medical professionals.

RECENT MARKET HAPPENINGS

• In May 2022, a research paper found that a novel biodegradable ureteral stent with an antibacterial ability can inhibit biofilm formation. A modified biodegradable PLACL was confirmed to have good hydrophilicity, which can resist protein adhesion, good biocompatible, and have excellent antibacterial ability, which could inhibit bacterial biofilm formation and kill free bacteria in the substrate.
• In February 2022, the Ultrathin Strut Orsiro Coronary Drug-Eluting Stent (DES) from BIOTRONIK establishes a new clinical standard. Orsiro's superior safety is confirmed by the final 5-year data from the BIOFLOW-V experiment, reinforcing Orsiro's position as the industry standard for DES.

MARKET SEGMENTATION

This research report on the global biodegradable stents market has been segmented and sub-segmented based on the product, application, absorption rate, end-use, see, and region.

By Product Type

• Polymeric Stents
• Metallic Alloy-based Stents
• Other Material-based Stents

By Application

• Coronary Artery Disease
• Peripheral Artery Disease

By Absorption Rate

• Slow Absorption Rate
• Intermediate Absorption Rate
• Fast Absorption Rate

By End User

• Hospital
• Cardiac Centers

By Region

• North America
• Europe
• Asia Pacific
• Middle East & Africa
• Latin America